Drug intelligence / Profile preview

rh-ES + CV

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

rh-ES + CV is a combination therapy consisting of recombinant human endostatin (rh-ES) and an agent abbreviated as "CV." Recombinant human endostatin is an endogenous broad-spectrum angiogenesis inhibitor, meaning it blocks the formation of new blood vessels that tumors need to grow. It has been shown to significantly improve therapeutic efficacy in cancer treatment when used in combination with other agents. The specific identity of "CV" in this context is not clarified in the available sources, but the combination is under clinical investigation for its anti-tumor effects[1].

Other names: recombinant human endostatin + CV

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on rh-ES + CV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rh-ES + CV.

Explore the full profile